军事知识服务平台
感染性角膜炎相关角膜胶原交联在细菌性角膜炎中的临床研究进展
Clinical research progress of the bacterial keratitis with photoactivated chromophore for infectious keratitis-corneal cross-linking
摘要 多重耐药菌株感染角膜严重威胁视力。近年来,随着病原体的耐药性增强,即便细菌性角膜炎(BK)获得了及时诊治,仍可能出现角膜溶解和角膜穿孔等并发症。因此,寻找新的治疗手段应对日益严重的耐药菌株感染性角膜炎至关重要。角膜胶原交联(CXL)已广泛用于圆锥角膜及屈光术后角膜扩张等疾病治疗,现已作为多重耐药微生物所致感染性角膜炎的辅助治疗方式。为区分CXL在感染性角膜炎与角膜扩张疾病中的应用,感染性角膜炎相关CXL被特称为PACK-CXL。现有研究结果表明,PACK-CXL作为抗生素治疗的辅助手段,在BK中具有有效性。本文中笔者就PACK-CXL的治疗机制及其在BK中的临床应用进展进行综述。
Abstract:
Multidrug-resistant bacterial keratitis poses a serious threat to vision. In recent years, as pathogens have become increasingly resistant to antibiotics, complications such as corneal melting and perforation may still occur even when bacterial keratitis (BK) is diagnosed and treated promptly. Therefore, it is critical to explore new therapeutic approaches to combat the growing challenge of drug-resistant infectious keratitis. Corneal collagen cross-linking (CXL), originally established for the treatment of keratoconus and post-refractive ectasia, has now been introduced as an adjunctive modality for infectious keratitis caused by multidrug-resistant organisms. To distinguish its application in infectious keratitis from that in ectatic disorders, CXL used for infectious keratitis has been termed photoactivated chromophore for infectious keratitis-corneal cross-linking (PACK-CXL). Current evidence indicates that PACK-CXL, as an adjunct to antibiotic therapy, is effective in treating BK. The therapeutic mechanisms of PACK-CXL and its clinical application in BK was summarized in this paper.
年,卷(期): 2026, 16(3)
在线出版日期: 2026年7月31日